Timber Pharmaceuticals, Inc. (TMBR)
|Net Income (ttm)||n/a|
|Trading Day||January 25|
|Day's Range||1.12 - 1.38|
|52-Week Range||0.26 - 4.11|
Dr. Mendelsohn has 20+ Years' Experience in Clinical Development and Medical Affairs
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022
Call to be held on Thursday, December 17th at 11:00am EST
Presentation on Tuesday December 15th at 10:40am EST
Biopharmx Corp shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was wel...
Timber Pharmaceuticals LLC, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. The company was founded in 2019 and is based in Woodcliff Lake, New Jersey.
|Stock Exchange |
|Ticker Symbol |
The average 12-month stock price forecast for TMBR is 2.25, which is an increase of 85.95% from the latest price.